Neurocrine Biosciences (NBIX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

NBIX Neurocrine Biosciences

Watchlist

135.990
-1.770-1.28%

Close Apr 26 16:00 ET

135.150
-0.840-0.62%

Post 17:10 ET

13.68BMarket Cap55.06P/E (TTM)

Full Hours

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Neurocrine Biosciences Upgraded at Wells Fargo on Pipeline
Seeking AlphaApr 24 11:59 ET
Jefferies Sticks to Its Buy Rating for Neurocrine (NBIX)
TipRanksApr 24 07:56 ET
Neurocrine Price Target Maintained With a $200.00/Share by Oppenheimer
Neurocrine Price Target Maintained With a $200.00/Share by Oppenheimer
Dow JonesApr 24 07:35 ET
Neurocrine Is Maintained at Outperform by Oppenheimer
Neurocrine Is Maintained at Outperform by Oppenheimer
Dow JonesApr 24 07:35 ET
Express News | Neurocrine Biosciences Inc : Wells Fargo Raises to Overweight From Equal Weight
Moomoo 24/7Apr 24 06:26 ET
Express News | HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $150 Price Target
Moomoo 24/7Apr 24 06:05 ET

Comments

Meltyy

Apr 9 23:48

FDA PDUFA Update…

🗓️ Last week’s PDUFAs:
$Supernus Pharmaceuticals(SUPN.US)$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech(LEGN.US)$ & $Johnson & Johnson(JNJ.US)$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca(AZN.US)$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio(TSVT.US)$ & $Bristol-Myers Squibb(BMY.US)$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals(VNDA.US)$...

Meltyy

Apr 1 16:25

PDUFA Calendar-April

The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
$Vanda Pharmaceuticals(VNDA.US)$$Legend Biotech(LEGN.US)$$Supernus Pharmaceuticals(SUPN.US)$$ImmunityBio(IBRX.US)$$Aquestive Therapeutics(AQST.US)$$X4 Pharmaceuticals(XFOR.US)$$Liquidia(LQDA.US)$$Neurocrine Biosciences(NBIX.US)$$Moderna(MRNA.US)$$Day One Biopharmaceuticals(DAWN.US)$
...

Mark Livermore

Mar 21 00:03

Watch, C&H 7w, (142.58/136.33-4.38%)

Stage 2 B/O, all time high, shakeout bar, darvas box/handle

Moomoo AI

Feb 16 18:57

Neurocrine Biosciences' earnings potential is seen as strong, despite unusual items impacting earnings. Profit performance is expected to improve next year.

The Strong Earnings Posted By Neurocrine Biosciences (NASDAQ:NBIX) Are A Good Indication Of The Strength Of The Business

Moomoo AI

Feb 14 19:47

Despite the slower growth in share price compared to earnings per share, the market remains optimistic about Neurocrine Biosciences, as indicated by its high P/E ratio. The recent positive sentiment and strong share price momentum may present an investment opportunity.